These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
286 related articles for article (PubMed ID: 35989423)
1. Systematic pan-cancer analysis identifies RBM39 as an immunological and prognostic biomarker. Zhang R; Wang W; Zhang N; Chen X; Liu W; Zhang L; Liu N J Cell Mol Med; 2022 Sep; 26(18):4859-4871. PubMed ID: 35989423 [TBL] [Abstract][Full Text] [Related]
2. HHLA2 Used as a Potential Prognostic and Immunological Biomarker and Correlated with Tumor Microenvironment in Pan-Cancer. Yang Z; Xu D; Ye X; Lin X; Zhang M; Su Y; Xie Q; Ni W Biomed Res Int; 2022; 2022():3924400. PubMed ID: 35252444 [TBL] [Abstract][Full Text] [Related]
3. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures. Zhang X; Wang Y; A G; Qu C; Chen J Front Immunol; 2021; 12():721030. PubMed ID: 34531868 [TBL] [Abstract][Full Text] [Related]
4. Pan-Cancer Analysis Revealed Liu J; Wang Y; Yin J; Yang Y; Geng R; Zhong Z; Ni S; Liu W; Du M; Yu H; Bai J J Oncol; 2022; 2022():3477148. PubMed ID: 35069733 [TBL] [Abstract][Full Text] [Related]
5. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers. Wang N; Zhu L; Wang L; Shen Z; Huang X Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736 [TBL] [Abstract][Full Text] [Related]
6. Systematic Pan-Cancer Analysis Identifies TREM2 as an Immunological and Prognostic Biomarker. Cheng X; Wang X; Nie K; Cheng L; Zhang Z; Hu Y; Peng W Front Immunol; 2021; 12():646523. PubMed ID: 33679809 [TBL] [Abstract][Full Text] [Related]
7. Pan-cancer and single-cell analysis reveal dual roles of lymphocyte activation gene-3 (LAG3) in cancer immunity and prognosis. Wang Y; Zhao Y; Zhang G; Lin Y; Fan C; Wei H; Chen S; Guan L; Liu K; Yu S; Fu L; Zhang J; Yuan Y; He J; Cai H Sci Rep; 2024 Oct; 14(1):24203. PubMed ID: 39406840 [TBL] [Abstract][Full Text] [Related]
8. Elucidating the pan-oncologic landscape of S100A9: prognostic and therapeutic corollaries from an integrative bioinformatics and Mendelian randomization analysis. Chen Y; Wu Z; Yi X Sci Rep; 2024 Aug; 14(1):19071. PubMed ID: 39154046 [TBL] [Abstract][Full Text] [Related]
9. Pan-cancer analysis from multi-omics data reveals AAMP as an unfavourable prognostic marker. Wang Y; Liu T; Zhang K; Huang RH; Jiang L Eur J Med Res; 2023 Jul; 28(1):258. PubMed ID: 37501187 [TBL] [Abstract][Full Text] [Related]
10. Pan-Cancer Analysis Based on Zhang Y; Wang S; Han S; Feng Y Front Oncol; 2022; 12():844794. PubMed ID: 35359375 [TBL] [Abstract][Full Text] [Related]
11. Pan-Cancer Analysis of PDIA3: Identifying It as a Potential Biomarker for Tumor Prognosis and Immunotherapy. Zhang J; Wang K; Hainisayimu T; Li H Oxid Med Cell Longev; 2022; 2022():9614819. PubMed ID: 36046686 [TBL] [Abstract][Full Text] [Related]
12. Comprehensive Pan-Cancer Analysis of KIF18A as a Marker for Prognosis and Immunity. Liu T; Yang K; Chen J; Qi L; Zhou X; Wang P Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830695 [TBL] [Abstract][Full Text] [Related]
13. Comprehensive pan-cancer analysis reveals prognostic implications of TMEM92 in the tumor immune microenvironment. Wu Z; Pan T; Li W; Zhang YH; Guo SH; Liu Y; Zhang L; Wang ZY Clin Transl Oncol; 2024 Oct; 26(10):2701-2717. PubMed ID: 38642258 [TBL] [Abstract][Full Text] [Related]
14. Differential Expression of the Hu J; Xu J; Feng X; Li Y; Hua F; Xu G Front Cell Dev Biol; 2021; 9():700661. PubMed ID: 34631699 [TBL] [Abstract][Full Text] [Related]
15. Systematic pan-cancer analysis identified neuropilin 1 as an immunological and prognostic biomarker. Ma X; Zhao Y; Shi C; Jiang H; Liu H; Wang H; Qin X; Wang Y; Han Z Cell Biochem Funct; 2023 Aug; 41(6):658-675. PubMed ID: 37306257 [TBL] [Abstract][Full Text] [Related]
16. Prognostic value and immunological role of PDCD1 gene in pan-cancer. Miao Y; Wang J; Li Q; Quan W; Wang Y; Li C; Wu J; Mi D Int Immunopharmacol; 2020 Dec; 89(Pt B):107080. PubMed ID: 33069926 [TBL] [Abstract][Full Text] [Related]
17. CXCL11 Correlates with Immune Infiltration and Impacts Patient Immunotherapy Efficacy: A Pan-Cancer Analysis. Li Y; Han S; Wu B; Zhong C; Shi Y; Lv C; Fu L; Zhang Y; Lang Q; Liang Z; Yu Y; Tian Y Front Immunol; 2022; 13():951247. PubMed ID: 35935945 [TBL] [Abstract][Full Text] [Related]
18. Pan-Cancer Integrated Analysis Identification of SASH3, a Potential Biomarker That Inhibits Lung Adenocarcinoma Progression. Chen X; Yuan Y; Ren W; Zhou F; Huang X; Pu J; Niu X; Jiang X Front Oncol; 2022; 12():927988. PubMed ID: 35756681 [TBL] [Abstract][Full Text] [Related]
19. Prognostic and immune regulating roles of YIF1B in Pan-Cancer: a potential target for both survival and therapy response evaluation. Liu J; Chen Z; Zhao P; Li W Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 32648580 [TBL] [Abstract][Full Text] [Related]
20. A prognostic and immunological analysis of 7B-containing Kelch structural domain (KLHDC7B) in pan-cancer: a potential target for immunotherapy and survival. Ding J; Ji X; Liu L; Chen DZ; Luo N; Yu XT; Guo F J Cancer Res Clin Oncol; 2023 Aug; 149(10):7857-7876. PubMed ID: 37039902 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]